Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Ipratropium bromide monohydrate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
Ipravent Inhaler contains a medicine called ipratropium bromide. This belongs to a group of medicines called bronchodilators. It is used to make breathing easier for people with asthma or 'chronic obstructive pulmonary disease' (COPD), often referred to as chronic bronchitis. If you have asthma or COPD, you may have difficulty in breathing, shortness of breath, wheezing or tightness in your chest. Ipravent Inhaler works by opening up airways.
2.
e Ipravent Inhaler
Do not use Ipravent Inhaler:
If you are not sure if any of these apply to you, talk to your doctor or pharmacist or asthma nurse before using Ipravent Inhaler. Ipratropium bromide is slow acting drug and therefore you will not get immediate relief after starting this medicine. Talk to your doctor, pharmacist, or asthma nurse:
Operations If you attend a hospital appointment or are admitted to hospital be sure to take your inhaler(s) and any other medicines (in their packaging if possible) with you. Some gases used in operations (anaesthetics gases) may affect how your inhaler works. If you are about to have surgery, make sure you mention that you are using Ipravent Inhaler to the doctor, dentist or anaesthetist. Ipravent Inhaler contains ethanol (alcohol) This medicine contains a small amount of ethanol (8.4 mg in one single dose).
3.
How to use Ipravent Inhaler
Always use this medicine exactly as described in this leaflet or as your doctor, pharmacist or asthma nurse has told you. Check with your doctor, pharmacist or asthma nurse if you are not sure. Use in children This pressurised metered dose inhaler is not to be used in children 12 years of age and younger or in adolescents 13 to 17 years of age. Use in adults (including the elderly) with either asthma or COPD
Testing your inhaler When you use the inhaler for the first time you should test it to check that it works properly. Also do this if you have not used the inhaler for 3 or more days. 1. Remove the mouthpiece cover by gently pressing the sides with your thumb and index finger. 2. Point the mouthpiece away from you and press the canister twice (once at a time) to release two puffs into the air.
your Inhaler
1. Stand or sit upright while using the Ipravent Inhaler 2. Remove the mouthpiece cover. 3. Check inside and outside the mouthpiece of the inhaler to make sure that it is clean and free from dust and dirt and any loose objects before inhaling. 4. Hold the inhaler upright between the thumb(s) on the base of the mouthpiece and a forefinger (s)/index finger(s) on the top of the inhaler (the arrow on the base of the container should be pointing upwards) and breathe out slowly and deeply. 5. Immediately after breathing out place the mouthpiece in your mouth between your teeth and close your lips around it but do not bite it 6. Breathe in slowly and deeply, through the mouth and immediately after starting to breathe in press down firmly on the top of the inhaler to release one actuation (puff) and continue to breathe in steadily and deeply. 7. Hold your breath, remove the inhaler from the mouth and take away the finger from top of the inhaler. Continue to hold your breath for as long as is comfortable, for 10 seconds if possible. 8. Breathe out slowly. Do not breathe out into the inhaler. 9. If a second inhalation is required you should wait at least one minute and then repeat steps 4 to 8. 10. Replace the mouthpiece cover after use.
IMPORTANT
If you use more Ipravent Inhaler than you should If you use more of this medicine than you should, talk to a doctor or go to a hospital straightaway. Take all your inhalers and any other medicines you are taking (in their packaging if possible) with you. If you take too much or too many puffs you may get a dry mouth, a rapid heart rate or blurred vision. If you forget to use your Ipravent Inhaler
Do not stop using your Ipravent Inhaler unless your doctor tells you to. If you have any further questions on the use of this medicine ask your doctor or pharmacist or asthma nurse.
4.
Like all medicines, this medicine can cause side effects, although not everybody gets them. Tell your doctor straight away if you notice any of the following serious side effects – you may need urgent medical treatment:
Ipravent Inhaler
Keep this medicine out of the sight and reach of children. Do not use Ipravent Inhaler after the expiry date which is stated on the carton and canister label after EXP. The expiry date refers to the last day of that month. Ipravent Inhaler should not be stored above 25oC. Keep away from direct sunlight, heat and frost. If the Inhaler has been exposed to low temperatures, the patient should take the metal canister out of the plastic case and warm it in their hands for a minimum of two minutes. The canister contains a pressurised liquid. Do not expose to temperatures higher than 50oC. Do not try to open, puncture or burn the canister even when apparently empty. Do not throw away any medicines or inhalers via waste water or household waste. Ask your pharmacist how to throw away medicines and inhalers that you no longer use. These measures will help protect the environment. 6.
What Ipravent Inhaler contains
and a plastic actuator made up of polypropylene having a white mouthpiece fitted with a green mouthpiece cover. Each carton contains one inhaler. Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder: Cipla (EU) Limited. Dixcart House, Addlestone Road, Bourne Business Park, Addlestone, Surrey, KT15 2LE, United Kingdom Manufacturer: S&D Pharma CZ, spol. s r.o, Theodor 28, 273 08 Pchery (Pharmos a.s. facility), Ceská Republika Cipla (EU) Limited, Dixcart House, Addlestone Road, Bourne Business Park, Addlestone, Surrey, KT15 2LE, United Kingdom Cipla Europe NV, De Keyserlei 58-60, Box 19, 2018 Antwerp, Belgium This leaflet was last revised in 01/2024.
Ipravent CFC-Free Inhaler 20 micrograms per actuation pressurised inhalation, solution comes as inhaler containing 20mcg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Ipravent CFC-Free Inhaler 20 micrograms per actuation pressurised inhalation, solution is ipratropium bromide monohydrate.
This leaflet reproduces the patient information leaflet approved for Ipravent CFC-Free Inhaler 20 micrograms per actuation pressurised inhalation, solution, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Ipravent CFC free Inhaler is indicated for the regular treatment of reversible bronchospasm associated with chronic obstructive pulmonary disease (COPD) and chronic asthma.
Posology
For inhalation use.
Children and adolescents
This pressurised metered dose inhaler is not to be used in children, 12 years of age and younger or adolescents 13 to 17 years of age.
Adults (including the elderly) with asthma or COPD
• 1 or 2 puffs to be inhaled three or four times daily.
• However, in early treatment some patients may need up to 4 puffs at a time to obtain maximum benefit.
The recommended dose should not be exceeded.
If therapy does not produce a significant improvement, if the patient's symptoms are getting worse or if a reduced response to treatment becomes apparent, medical advice must be sought. In the case of acute or rapidly worsening dyspnoea (difficulty in breathing) a doctor should be consulted immediately.
Method of administration
The correct administration of ipratropium bromide from the inhaler is essential for successful therapy. It is imperative that patient's inhaler technique should be checked to ensure optimum drug delivery of ipratropium bromide to the lungs from time to time.
It is advised to read the Patient Information Leaflet carefully before using this inhaler and to take note regarding how to use the inhaler, how to inhale from the inhaler correctly and how to clean the inhaler.
The canister should be pressed twice to release two metered doses into the air before the inhaler is used for the first time, or when the inhaler has not been used for 3 days or more, to ensure that the inhaler is working properly and that it is ready for use.
On each occasion on which the inhaler is used the following instructions should be followed:
1. Stand or sit upright while using the Ipravent Inhaler
2. Remove the mouthpiece cover.
3. Check inside and outside the mouthpiece of the inhaler to make sure that it is clean and free from dust and dirt and any loose objects before inhaling.
4. Hold the inhaler upright between the thumb(s) on the base of the mouthpiece and a forefinger(s)/index finger(s) on the top of the inhaler (the arrow on the base of the container should be pointing upwards), breathe out for as long as is comfortable, and as slowly and deeply as possible.
5. Immediately after breathing out place the mouthpiece in your mouth between your teeth and close your lips around it but do not bite it
6. Breathe in slowly and deeply, through the mouth and immediately after starting to breathe in press down firmly on the top of the inhaler to release one actuation (puff) and continue to breathe in steadily and deeply.
7. Hold the breath, remove the inhaler from the mouth and take away the finger from top of the inhaler. Continue to hold the breath for as long as is comfortable, for 10 seconds if possible.
8. Breathe out slowly Do not breathe out into the inhaler.
9. If a second inhalation is required you should wait at least one minute and then repeat steps 4 to 8.
10. Replace the mouthpiece cover after use.
IMPORTANT
• Do not inhale too quickly, start breathing in as slowly and steadily as possible just before pressing the inhaler
• Do not rush through the entire procedure
• Elderly patients and patients with weak hands may use the inhaler with both hands
• Practice inhalation technique in front of a mirror; if a mist is seen following inhalation, either from the inhaler itself or from the sides of the mouth, the inhalation procedure should be repeated
Cleaning
It is important to clean your inhaler regularly. Otherwise it may not work properly.
• Remove the canister and green mouthpiece cover.
• Wash and clean the white mouthpiece in warm soapy water.
• Rinse in warm water and allow to air dry without using any heating system.
• Make sure the small hole in the mouthpiece is washed through thoroughly.
Once the white mouthpiece is dry, replace the canister and the cap
DO NOT PUT THE METAL CANISTER INTO WATER
Please read the Patient Information Leaflet for appropriate instructions for use/inhalation
The inhaler can be used with the Aerochamber Plus spacer device. This may be useful for patients, e.g. adult, who find it difficult to synchronise breathing in and inhaler actuation.
The canister is not transparent. It is therefore not possible to see when it is empty. The inhaler will deliver 200 actuations. When these have all been used (usually after 3 - 4 weeks of regular use) the inhaler may still appear to contain a small amount of fluid. However the inhaler should be replaced in order to ensure that each metered dose contains the correct amount of medicine.
If the Inhaler has been exposed to low temperatures, the patient should take the metal canister out of the plastic case and warm it in their hands for a minimum of two minutes.
WARNING
The plastic mouthpiece has been specially designed for use with Ipravent CFC-Free Inhaler to ensure that each metered dose contains the correct amount of medicine. The mouthpiece must never be used with any other metered dose inhaler nor must Ipravent CFC-Free Inhaler be used with any mouthpiece other than the one supplied with the product.
The mouthpiece should always be kept clean (as per the cleaning procedure mentioned above)
Ipratropium bromide should not be used by patients with known hypersensitivity to atropine or its derivatives, or to ipratropium bromide or to any of the excipients listed in section 6.1.
Increasing use of any as required short-acting β2 adrenoceptor agonist bronchodilators to relieve asthma symptoms, lack of relief from as required short-acting β2 adrenoceptor agonist bronchodilators, short-acting bronchodilators becoming ineffective and/or increasing symptoms indicate deterioration of asthma control and patients should be reviewed by a doctor
It should be noted that an exacerbation of the clinical symptoms of asthma may be due to an acute respiratory tract bacterial infection and treatment may require appropriate antibiotics, an increase in the dose of any inhaled corticosteroids and/or a short course of oral conrticosteroids. A rapid acting, short acting inhaled β2 adrenoceptor agonist should always be available as rescue medication.
Hypersensitivity reactions following the use of ipratropium bromide have been seen and have presented as urticaria, angioedema, rash, bronchospasm, oropharyngeal oedema and anaphylaxis.
Caution is advocated in the use of anticholinergic agents in patients predisposed to or with narrow-angle glaucoma, or with pre-existing urinary outflow tract obstruction (e.g. prostatic hyperplasia or bladder-outflow obstruction).
As patients with cystic fibrosis may be prone to gastrointestinal motility disturbances, ipratropium bromide, as other anticholinergics, should be used with caution in these patients.
There have been isolated reports of ocular complications (i.e. mydriasis, increased intraocular pressure, narrow-angle glaucoma, eye pain) when aerosolised ipratropium bromide, either alone or in combination with a β2 adrenoceptor agonist, has come into contact with the eyes. Thus patients must be instructed in the correct administration of ipratropium bromide and warned against the accidental release of the contents of the inhaler into the eye. Since ipratropium bromide is inhaled via a mouthpiece and with manual control, the risk of the mist entering the eyes is limited. Antiglaucoma therapy is effective in the prevention of acute narrow-angle glaucoma in susceptible individuals and patients who may be susceptible to glaucoma should be warned specifically on the need for ocular protection.
Eye pain or discomfort, blurred vision, visual halos or coloured images in association with red eyes from conjunctival congestion and corneal oedema may be signs of acute narrow-angle glaucoma. Should any combination of these symptoms develop, treatment with miotic drops should be initiated and specialist advice sought immediately.
Patients should be informed when starting treatment that the onset of action of ipratropium bromide is slower than that of inhaled sympathomimetic bronchodilators.
As with other inhalation therapy paradoxical bronchospasm may occur with an immediate increase in wheezing and shortness of breath after dosing. Paradoxical bronchospasm responds to a rapid –acting inhaled bronchodilator and should be treated straightaway. Ipravent CFC-Free Inhaler should be discontinued immediately, the patient assessed and alternative therapy instituted if necessary.
This medicinal product contains a small amount of ethanol (8.4 mg in one single dose).
Ipratropium bromide has not been studied in patients with hepatic or renal insufficiency. It should be used with caution in these patient populations
There is evidence that the administration of ipratropium bromide with beta-adrenergic medicinal products and xanthine preparations may produce an additive bronchodilatory effect.
There is no experience of the use of this product in pregnancy and lactation in humans. It should not be used in pregnancy or lactation unless the expected benefits to the mother are thought to outweigh any potential risks to the fetus or neonate.
Pregnancy
The safety of ipratropium bromide during human pregnancy has not been established. The benefits of using ipratropium bromide during a confirmed or suspected pregnancy must be weighed against the possible hazards to the unborn child. Preclinical studies have shown no embryotoxic or teratogenic effects following inhalation or intranasal application at doses considerably higher than those recommended in man.
Breastfeeding
It is not known whether ipratropium bromide is excreted into breast milk. It is unlikely that ipratropium bromide would reach the infant to an important extent, however caution should be exercised when ipratropium bromide is administered to nursing mothers.
Studies of HFA-134a administered to pregnant and lactating rats and rabbits have not revealed any special hazard.
Fertility
Preclinical studies performed with ipratropium bromide showed no adverse effect on fertility (see section 5.3). Clinical data on fertility are not available for ipratropium bromide. Therefore in case of planned pregnancy the product should be used with caution after consultation with doctor.
Ipratropium bromide has a moderate influence on the ability to drive or use machines.
No studies on the effects on the ability to drive and use machines have been performed. However patients should be advised that they may experience undesirable effects such as dizziness, accommodation disorder, mydriasis, blurred vision, visual halos and/or coloured images, red eyes, eye pain or discomfort during treatment with ipratropium bromide. If patients experience the above mentioned side effects they should avoid potentially hazardous tasks such as driving or operating machinery and should contact their doctor straightaway.
If the eyes are affected in any way at all do not drive or operate machinery. Contact your doctor.
Many of the listed undesirable effects can be assigned to the anticholinergic properties of ipratropium bromide. As with all inhalation therapy ipratropium bromide may show symptoms of local irritation.
Adverse drug reactions were identified from data obtained in clinical trials and pharmacovigilance during post approval use of the medicinal product.
The most frequent side effects known from clinical trials were headache, throat irritation, cough, dry mouth, gastro-intestinal motility disorders (including constipation, diarrhea and vomiting), nausea, and dizziness.
Frequencies
Very common ≥ 1/10
Common ≥ 1/100 to < 1/10
Uncommon ≥ 1/1,000 to < 1/100
Rare ≥ 1/10,000 to < 1/1,000
Very rare < 1/10,000
Immune system disorder
Hypersensitivity (1)
Uncommon
Anaphylactic reaction
Uncommon
Angioedema of tongue, lips and face
Uncommon
Nervous system disorders
Headache
Common
Dizziness
Common
Eye disorders
Blurred vision
Uncommon
Mydriasis (2)
Uncommon
Intraocular pressure increased (2)
Uncommon
Glaucoma (2)
Uncommon
Eye pain (2)
Uncommon
Halo vision
Uncommon
Conjunctival hyperaemia
Uncommon
Corneal oedema
Uncommon
Accommodation disorder
Rare
Cardiac disorders
Palpitations
Uncommon
Supraventricular tachycardia
Uncommon
Atrial fibrillation
Rare
Heart rate increased
Rare
Respiratory, thoracic and mediastinal disorders
Throat irritation
Common
Cough
Common
Bronchospasm
Uncommon
Paradoxical bronchospasm(3)
Uncommon
Laryngospasm
Uncommon
Pharyngeal oedema
Uncommon
Dry throat
Uncommon
Gastro-intestinal disorders
Dry mouth
Common
Nausea
Common
Gastro-intestinal motility disorder
Common
e.g. Diarrhoea
Uncommon
Constipation
Uncommon
Vomiting
Uncommon
Stomatitis
Uncommon
Skin and subcutaneous tissue disorders
Rash
Uncommon
Pruritus
Uncommon
Urticaria
Rare
Renal and urinary disorders
Urinary retention (4)
Uncommon
(1) Hypersensitivity reactions following the use of ipratropium bromide have been seen and have presented as urticaria, angioedema, rash, bronchospasm, oropharyngeal oedema and anaphylaxis. If severe allergic reactions occur, ipratropium bromide should be discontinued immediately, do not use your Ipravent CFC-Free Inhaler again, talk to your doctor or pharmacist immediately.
(2) Ocular complications have been reported when aerolised ipratropium bromide, either alone or in combination with an β2 adrenoceptor agonist, has come into contact with the eyes - see section 4.4.
(3) As with other inhalation therapy paradoxical bronchospasm may occur with an immediate increase in wheezing and shortness of breath after dosing. Paradoxical bronchospasm responds to a rapid –acting inhaled bronchodilator and should be treated straightaway. Ipratropium bromide should be discontinued immediately, the patient assessed and alternative therapy instituted if necessary.
(4) The risk of urinary retention may be increased in patients with pre-existing urinary outflow tract obstruction.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.
No symptoms specific to overdosage have been encountered. In view of the wide therapeutic window and topical administration of ipratropium bromide, no serious anticholinergic symptoms are to be expected. As with other anticholinergics, dry mouth, visual accommodation disturbances and tachycardia would be the expected symptoms and signs of overdose.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Medicines sold in Poland with the same active substance: W Polsce znany jako
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Ipravent CFC-Free Inhaler 20 micrograms per actuation pressurised inhalation, solution. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.